Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Mar 17, 2011

Premium

Exiqon this week launched 235 additional pre-validated miRcury LNA Universal RT microRNA qPCR assays for sensitive and specific quantification of miRNAs.

With the launch, Exiqon now offers 1,731 pre-validated qPCR assays for human, mouse, and rat miRNAs. In addition, Exiqon offers custom-designed LNA-enhanced qPCR assays for any miRNA.


Bio-Rad this week introduced CFX Manager 2.0, real-time PCR experiment setup and data-analysis software for use with the company's CFX96, CFX384, and MiniOpticon real-time PCR systems.

Combined with Biogazelle's qbasePlus software, which is included with the CFX96 and CFX384 systems, CFX Manager 2.0 enhances researchers' ability to comply with the emerging standard, minimum information for publication of quantitative real-time PCR experiments, or MIQE.

CFX Manager's terminology is consistent with MIQE guidelines, and data can be exported in the recommended RDML file format for submission with a manuscript or for import into qbasePLUS software.

CFX Manager 2.0 also features Scheduler Streamline experiment setup; Master Mix Calculator, Custom Data View, and Custom Data Export.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.